To assess whether resuscitation with albumin-containing solutions, compared with other fluids, is associated with lower mortality in patients with sepsis.
MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases, the metaRegister of Controlled Trials, and the Medical Editors Trial Amnesty Register.
Prospective randomized clinical trials of fluid resuscitation with albumin-containing solutions compared with other fluid resuscitation regimens, which included a population or subgroup of participants with sepsis, were included.
Assessment of the validity of included studies and data extraction were conducted independently by two authors.
For the primary analysis, the effect of albumin-containing solutions on all-cause mortality was assessed by using a fixed-effect meta-analysis.
Seventeen studies that randomized 1977 participants were included in the meta-analysis. There were eight studies that included only patients with sepsis and nine where patients with sepsis were a subgroup of the study population. There was no evidence of heterogeneity, I2 = 0%. The use of albumin for resuscitation of patients with sepsis was associated with a reduction in mortality with the pooled estimate of the odds ratio of 0.82 (95% confidence limits 0.67–1.0, p = .047).
In this meta-analysis, the use of albumin-containing solutions for the resuscitation of patients with sepsis was associated with lower mortality compared with other fluid resuscitation regimens. Until the results of ongoing randomized controlled trials are known, clinicians should consider the use of albumin-containing solutions for the resuscitation of patients with sepsis.
SUPPLEMENTAL DIGITAL CONTENT IS AVAILABLE IN THE TEXT.
From the Northern Clinical School (APD, SF), Sydney Medical School, University of Sydney, Sydney, Australia; Intensive Care Unit (APD, AD, SF), Royal North Shore Hospital, St. Leonards, Australia; Department of Anaesthesia and Critical Care (JM), Belfast City Hospital, Belfast, United Kingdom; and The George Institute for Global Health (AD, SF), Sydney, Australia.
The SAFE Study Investigators received a grant from CSL Bioplasma and Prof. Finfer was one of the SAFE study investigators. The remaining authors have not disclosed any potential conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ccmjournal.com).
For information regarding this article, E-mail: email@example.com